Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
sharp increase » year increase (Expand Search)
Showing 981 - 1,000 results of 21,625 for search '(( significant decrease decrease ) OR ( significant ((largest decrease) OR (sharp increase)) ))', query time: 0.38s Refine Results
  1. 981
    Correlation between protein abundances and R<sub>5-20</sub> z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (<i>TF, Serotransferrin; F2, Prothrombin; CFI, Complement factor I; HPX, Hemopexin; C4A/C4B, Complement C4b; GC, Vitamin D-binding protein; SERPINA7, Thyroxine-binding globulin; CFB, Complement factor B; APOH, Beta-2-glycoprotein 1; NTM, Neurotrimin</i>).

    Correlation between protein abundances and R<sub>5-20</sub> z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (... by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 982
    General characteristics and clinical data of the subjects included in the study.

    General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 983
    Distribution of average relative amounts of lipid classes.

    Distribution of average relative amounts of lipid classes. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 984
    Flow chart on the inclusion and drop out of patients.

    Flow chart on the inclusion and drop out of patients. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 985
    Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls.

    Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 986
    Symptoms reported by COVID-19 cases at baseline and at follow-up.

    Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 987
    Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means.

    Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

    Published 2025
    Save to List
    Saved in:
  8. 988
    Effects of BM-MSCs on ROS generation in DCS rats.

    Effects of BM-MSCs on ROS generation in DCS rats. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 989
    Pretreatment of BM-MSCs attenuates DCS induced lung inflammation.

    Pretreatment of BM-MSCs attenuates DCS induced lung inflammation. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 990
    Isotype control overlays.

    Isotype control overlays. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 991
    The mean and standard deviation of parameters.

    The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 992
    Original uncropped blot.

    Original uncropped blot. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 993
    Characterization of BM-MSC.

    Characterization of BM-MSC. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 994
    Pretreatment of BM-MSCs improves the survival rate and incidence of DCS.

    Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 995
    Utilization of anticoagulants at eight hospitals from 2019 to 2023.

    Utilization of anticoagulants at eight hospitals from 2019 to 2023. by Wei Luo (80175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 996
    The ANCOVA and Post_hoc results.

    The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 997
    The demographical and clinical characteristics of subjects at baseline.

    The demographical and clinical characteristics of subjects at baseline. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 998
    Identification of BM-MSCs.

    Identification of BM-MSCs. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 999
    CONSORT flowchart.

    CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 1000
    Effect of BM-MSCs in improving DCS induced lung injury.

    Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: